The End of the American Cash Cow?
The weapon of choice here is something called the ‘Most-Favoured-Nation’ standard. It sounds terribly official, but the concept is one any savvy shopper would understand. Why should you pay more for the same product than your neighbour? The directive essentially says that drug companies must offer American patients the lowest price they charge in any other developed country.
Let’s put that into perspective. Imagine a life-saving treatment costs, say, £3,000 a month in the UK, a price negotiated by the NHS. The very same pill, from the same factory, might be sold for £8,000 a month in America. Under this new proposal, the US price would have to drop to the UK level. You don’t need to be a financial wizard to see what that does to a company’s profit margins. For firms that have built their empires on the back of American premium pricing, this is nothing short of a revolution.